Fertin Pharma's revenue decreased – but CEO anticipates future growth

Fertin Pharma's latest annual report reveals a declined revenue and operating profit, but CEO Søren Birn is ready with a growth plan that involves much more than nicotine chewing gum.

Photo: Ritzau Scanpix/Sebastian Buur Gunvald

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles